Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-14
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.